Dyspnea Worsens in 1 in 3 Patients Following Discharge from HF Hospitalization - HCPLive
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Quin Denfeld, PhD, discusses her findings from the BIOMES-HF study, indicating worsening symptoms in patients with HF over time. Although dyspnea generally improves in patients after heart failure (HF) hospitalization, symptoms can remain persistent or worsen in >1/3 of all cases, according to data from the BIOMES-HF study.1 Quin Denfeld, PhD, associate professor at Oregon Health & Science University, presented these data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, Arizona, by Quin Denfeld, PhD, associate professor at Oregon Health & Science University. In an interview with HCPLive, Denfeld discussed the implications of her research and why these symptoms are critically important.1“The cardinal symptom of heart failure is dyspnea, or shortness of breath. That’s what brings people into the hospital,” Denfeld told HCPLive. “We wanted to see, after that hospitalization, how did these patients fare afterwards in terms of their dyspnea? Did it go up? Did it go down?
This article is an excerpt. To read the full content, visit the original source. HCPLive
Related articles
Flyers' early adversity worsens with injuries to key pieces - NBC Sports Philadelphia
Travis Konecny, Cam York and Rasmus Ristolainen were all out Saturday with injuries. The Flyers Pregame Live crew breaks down how the absences of Travis Konecny and Cam York will impact the team against the Bruins.
Bioengineer.org | Switching HIV drugs or adding zoledronic acid rebuilds bone lost to tenofovir - European AIDS Treatment Group
Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.
0 comments
No comments yet. Be the first to share your thoughts!